{
 "as_of": "2026-11-11",
 "cmr": "se-cm-kg/XSTO/SE0029278555",
 "fence": "The page is the record's research on the issuer — no analyst, no rating, no view.",
 "markdown": "The page is the record's research on the issuer — no analyst, no rating, no view.\n\n# Active Biotech AB (Nasdaq Stockholm: SE0029278555) — research page\n\nAs of 2026-11-11 · se-cm-kg · record version 1\n\n## Identity and listing\n\nThe issuer is Active Biotech AB, listed on Nasdaq Stockholm under ticker SE0029278555 with ISIN SE0029278555 and LEI 549300OJ44CLMRU8YE43. Security type, segment, sector and jurisdiction are not on the record. The listing status is listed, not halted.\n\n## The disclosure read\n\nThe record holds 24 filings on 23 filing days in the window 2025-11-11 to 2026-11-11. The median gap between filing days is 12.0 days, and the latest filing is 6 days before the record date of 2026-11-11. Nasdaq Stockholm peers have a median of 30.0 filings, a median cadence gap of 9.5 days and a median latency of 7.0 days across 398 issuers. Sector peer figures are not on the record. The latest filing is dated 2026-11-05 and is of type Interim report (Q1 and Q3).\n\n## Auditor\n\nThe auditor of record is not on the record, and neither is its location. Auditor changes are not on the record, as this market's register has no lifecycle type map yet.\n\n## Events and halts\n\nListing, delisting, name change, domicile change and segment move are not on the record, as this market's register has no lifecycle type map yet. The halt flag is listed, not halted.\n\n## Orderability\n\nThe orderability outcome is not determinable. The chapter's orderability section carries no client categories, so the outcome cannot name its client category. The rule version is acm-68000/se/mifid-ii-product-governance/r1, and the chapter is as of 2026-11-04.\n\n## Coverage\n\nNo research houses were found on the investor-relations pages read, so the count is 0.\n\n## Open research\n\nThe record holds 3 openly published research notes, all by Redeye: 2020-12-13, 2022-04-22 and 2022-11-03.\n\n## Licensed\n\nLicensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.\n\n## As-of depth\n\nThe market's vintage is not sealed. No issuer years are sealed, the market's earliest sealed date is not on the record, and the live record start is not on the record.\n\n## Sources\n\n9 source pages are named on this page; every value above carries its own source page and read date in the numbers.\n\n- https://firds.esma.europa.eu/firds/ (identity.exchange)\n- https://mapping.gleif.org/api/v2/isin-lei/latest/download (identity.lei)\n- https://mcp.se-cm-kg.ai/events/XSTO/SE0029278555 (the disclosure lines)\n- https://api.news.eu.nasdaq.com/news/query.action?globalGroup=exchangeNotice&globalName=ExchangenewsFilter|FirstNorthInformation (the halt flag)\n- https://se.eu-cm-kg.ai/book/aio.json (the orderability chapter)\n- https://www.activebiotech.com/wp-content/uploads/Redeye-active-biotech-q3-2022-approaching-important-milestones-2_ob2rcp.pdf (open research)\n- https://www.activebiotech.com/wp-content/uploads/Redeye_Active_Biotech_Note_Q1_2022.pdf (open research)\n- https://www.activebiotech.com/wp-content/uploads/active-biotech-initation-201214.pdf (open research)\n- https://mcp.se-cm-kg.ai/record/XSTO/SE0029278555 (the record)\n",
 "market": "SE",
 "node": "se-cm-kg",
 "numbers": {
  "as_of_depth": {
   "issuer_years_sealed": [],
   "live_record_began": null,
   "node_history_from": null,
   "node_years_sealed": [],
   "note": "the SE vintage is not sealed; the record is the live record as of 2026-11-11",
   "record_version": 1,
   "sealed": false
  },
  "auditor": {
   "auditor": {
    "market": "SE",
    "state": "not_on_record"
   },
   "auditor_firm_id": {
    "market": "SE",
    "state": "not_on_record"
   },
   "auditor_location": {
    "market": "SE",
    "state": "not_on_record"
   },
   "changes": {
    "market": "SE",
    "reason": "no lifecycle type map for this register yet (SHELF-01: us and ca first)",
    "state": "not_on_record"
   }
  },
  "cmr": "se-cm-kg/XSTO/SE0029278555",
  "coverage": {
   "count": 0,
   "houses": [],
   "pages_checked": [
    {
     "page": "https://www.activebiotech.com/en/investor/analysts/",
     "result": "not readable by this rail (404)"
    }
   ],
   "read_by": "Perplexity sonar (search) · page read by this rail",
   "read_date": "2026-11-12",
   "since": null,
   "state": "none_found"
  },
  "disclosure": {
   "against": {
    "exchange": {
     "issuers": 398,
     "median_cadence_gap_days": 9.5,
     "median_filings": 30,
     "median_latency_days": 7,
     "name": "Nasdaq Stockholm"
    },
    "sector": {
     "market": "SE",
     "state": "not_on_record"
    }
   },
   "by_type": {
    "Annual Financial Report": 1,
    "Decisions of general meeting": 2,
    "Financial Statement Release": 1,
    "Half Year financial report": 1,
    "Interim report (Q1 and Q3)": 2,
    "Investor News": 9,
    "Notice to general meeting": 1,
    "Other information disclosed according to the rules of the Exchange": 5,
    "Total number of voting rights and capital": 2
   },
   "cadence_median_gap_days": 12,
   "filing_days": 23,
   "filings": 24,
   "latency_days": 6,
   "latest": [
    {
     "category": "Interim report (Q1 and Q3)",
     "date": "2026-11-05",
     "source": "https://view.news.eu.nasdaq.com/view?id=b75c86c56e3a730db9514ac2cce3e7b1e&lang=en&src=listed",
     "title": "Active Biotech Interim Report Q3 2026",
     "type": "Interim report (Q1 and Q3)"
    },
    {
     "category": "Investor News",
     "date": "2026-10-13",
     "source": "https://view.news.eu.nasdaq.com/view?id=be5f92cbde75d7b77945e664bcd5ce3fe&lang=en&src=listed",
     "title": "First cohort under amended protocol succesfully completes safety evaluation in HOVON 172 MF clinical study of tasquinimod in myelofibrosis",
     "type": "Investor News"
    },
    {
     "category": "Investor News",
     "date": "2026-09-30",
     "source": "https://view.news.eu.nasdaq.com/view?id=bc97405c90433d3e54d8db7ec82d99f7b&lang=en&src=listed",
     "title": "Active Biotech Strengthens Global Patent Protection for Laquinimod with Patent Grant in Japan",
     "type": "Investor News"
    },
    {
     "category": "Half Year financial report",
     "date": "2026-08-20",
     "source": "https://view.news.eu.nasdaq.com/view?id=bba00c39195eb23daab86235735060128&lang=en&src=listed",
     "title": "Active Biotech Interim Report Q2 2026",
     "type": "Half Year financial report"
    },
    {
     "category": "Investor News",
     "date": "2026-08-18",
     "source": "https://view.news.eu.nasdaq.com/view?id=b46ce5f622e7f2d414a63819571d73fed&lang=en&src=listed",
     "title": "Active Biotech expands US collaboration to advance tasquinimod clinical development in myelofibrosis",
     "type": "Investor News"
    }
   ],
   "latest_filing_date": "2026-11-05",
   "read": "the node's event lines (list_events_since), as get_filings serves them",
   "source": "https://mcp.se-cm-kg.ai/events/XSTO/SE0029278555",
   "window": {
    "from": "2025-11-11",
    "to": "2026-11-11"
   }
  },
  "identity": {
   "exchange": {
    "read_by": "allooloo-cm-kg/eu-sources/se roster.py",
    "read_date": "2026-11-11",
    "read_date_basis": "the record version as_of",
    "source": "https://firds.esma.europa.eu/firds/ (ESMA FIRDS FULINS_E 2026-11-07: FULINS_E_20261107_01of02.zip, FULINS_E_20261107_02of02.zip)",
    "state": "sourced",
    "value": "Nasdaq Stockholm"
   },
   "isin": {
    "read_by": "allooloo-cm-kg/eu-sources/se roster.py",
    "read_date": "2026-11-11",
    "read_date_basis": "the record version as_of",
    "source": "https://firds.esma.europa.eu/firds/ (ESMA FIRDS FULINS_E 2026-11-07: FULINS_E_20261107_01of02.zip, FULINS_E_20261107_02of02.zip)",
    "state": "sourced",
    "value": "SE0029278555"
   },
   "jurisdiction": {
    "market": "SE",
    "state": "not_on_record"
   },
   "lei": {
    "read_by": "GLEIF ISIN-to-LEI mapping file (daily), LEI by exact ISIN",
    "read_date": "2026-11-12",
    "read_date_basis": "the field",
    "source": "https://mapping.gleif.org/api/v2/isin-lei/latest/download (ISIN SE0029278555)",
    "state": "sourced",
    "value": "549300OJ44CLMRU8YE43"
   },
   "name": {
    "read_by": "allooloo-cm-kg/eu-sources/se roster.py",
    "read_date": "2026-11-11",
    "read_date_basis": "the record version as_of",
    "source": "https://firds.esma.europa.eu/firds/ (ESMA FIRDS FULINS_E 2026-11-07: FULINS_E_20261107_01of02.zip, FULINS_E_20261107_02of02.zip)",
    "state": "sourced",
    "value": "Active Biotech AB"
   },
   "sector": {
    "market": "SE",
    "state": "not_on_record"
   },
   "security_type": {
    "market": "SE",
    "state": "not_on_record"
   },
   "segment": {
    "market": "SE",
    "state": "not_on_record"
   },
   "ticker": {
    "read_by": "allooloo-cm-kg/eu-sources/se roster.py",
    "read_date": "2026-11-11",
    "read_date_basis": "the record version as_of",
    "source": "https://firds.esma.europa.eu/firds/ (ESMA FIRDS FULINS_E 2026-11-07: FULINS_E_20261107_01of02.zip, FULINS_E_20261107_02of02.zip)",
    "state": "sourced",
    "value": "SE0029278555"
   },
   "website": {
    "market": "SE",
    "state": "not_on_record"
   }
  },
  "licensed": {
   "columns": [
    "licensor",
    "entitlement",
    "title",
    "date",
    "source"
   ],
   "rows": [],
   "rule": "A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded."
  },
  "lifecycle": {
   "delisting": {
    "market": "SE",
    "reason": "no lifecycle type map for this register yet (SHELF-01: us and ca first)",
    "state": "not_on_record"
   },
   "domicile_change": {
    "market": "SE",
    "reason": "no lifecycle type map for this register yet (SHELF-01: us and ca first)",
    "state": "not_on_record"
   },
   "listing": {
    "market": "SE",
    "reason": "no lifecycle type map for this register yet (SHELF-01: us and ca first)",
    "state": "not_on_record"
   },
   "name_change": {
    "market": "SE",
    "reason": "no lifecycle type map for this register yet (SHELF-01: us and ca first)",
    "state": "not_on_record"
   },
   "segment_move": {
    "market": "SE",
    "reason": "no lifecycle type map for this register yet (SHELF-01: us and ca first)",
    "state": "not_on_record"
   }
  },
  "market": "SE",
  "node": "se-cm-kg",
  "numbers_hash": "sha256:fbcb86f4167db0eb7582c536509f0d79c8acb57790e19712f1d9454f9d05f36d",
  "open_research": {
   "read_date": "2026-11-12",
   "rows": [
    {
     "date": "2022-11-03",
     "kind": "independent",
     "publisher": "Redeye",
     "read_by": "the note's link answers (200 application/pdf); a document, not read as text",
     "read_date": "2026-11-12",
     "source": "https://www.activebiotech.com/wp-content/uploads/Redeye-active-biotech-q3-2022-approaching-important-milestones-2_ob2rcp.pdf",
     "state": "sourced",
     "title": "Active Biotech Q3 2022: Approaching important milestones"
    },
    {
     "date": "2022-04-22",
     "kind": "independent",
     "publisher": "Redeye",
     "read_by": "the note's link answers (200 application/pdf); a document, not read as text",
     "read_date": "2026-11-12",
     "source": "https://www.activebiotech.com/wp-content/uploads/Redeye_Active_Biotech_Note_Q1_2022.pdf",
     "state": "sourced",
     "title": "Active Biotech Q1’22: Our comments and updated valuation"
    },
    {
     "date": "2020-12-13",
     "kind": "independent",
     "publisher": "Redeye",
     "read_by": "the note's link answers (200 application/pdf); a document, not read as text",
     "read_date": "2026-11-12",
     "source": "https://www.activebiotech.com/wp-content/uploads/active-biotech-initation-201214.pdf",
     "state": "sourced",
     "title": "Derisked and Repurposed"
    }
   ],
   "state": "found"
  },
  "orderability": {
   "chapter_as_of": "2026-11-04",
   "client_categories": [],
   "determinable": false,
   "read": {
    "chapter": "https://se.eu-cm-kg.ai/book/aio.json",
    "door": "https://se.eu-cm-kg.ai/mcp",
    "tool": "get_orderability"
   },
   "reason": "the chapter's orderability section carries no client_categories: the outcome cannot name its client category",
   "rule_version": "acm-68000/se/mifid-ii-product-governance/r1",
   "section": "se.aio.v5"
  },
  "record": {
   "as_of": "2026-11-11",
   "url": "https://mcp.se-cm-kg.ai/record/XSTO/SE0029278555",
   "version": 1
  },
  "schema": "research-numbers v0.1 (USR-01, 2026-11-11)",
  "status": {
   "read_date": "2026-11-12",
   "source": "https://api.news.eu.nasdaq.com/news/query.action?globalGroup=exchangeNotice&globalName=ExchangenewsFilter|FirstNorthInformation",
   "value": "listed, not halted"
  }
 },
 "numbers_hash": "sha256:fbcb86f4167db0eb7582c536509f0d79c8acb57790e19712f1d9454f9d05f36d",
 "path": "/se/XSTO/SE0029278555",
 "schema": "research-page v0.1 (USR-02, 2026-11-11)",
 "sections": [
  {
   "id": "identity",
   "text": "The issuer is Active Biotech AB, listed on Nasdaq Stockholm under ticker SE0029278555 with ISIN SE0029278555 and LEI 549300OJ44CLMRU8YE43. Security type, segment, sector and jurisdiction are not on the record. The listing status is listed, not halted.",
   "title": "Identity and listing"
  },
  {
   "id": "disclosure",
   "text": "The record holds 24 filings on 23 filing days in the window 2025-11-11 to 2026-11-11. The median gap between filing days is 12.0 days, and the latest filing is 6 days before the record date of 2026-11-11. Nasdaq Stockholm peers have a median of 30.0 filings, a median cadence gap of 9.5 days and a median latency of 7.0 days across 398 issuers. Sector peer figures are not on the record. The latest filing is dated 2026-11-05 and is of type Interim report (Q1 and Q3).",
   "title": "The disclosure read"
  },
  {
   "id": "auditor",
   "text": "The auditor of record is not on the record, and neither is its location. Auditor changes are not on the record, as this market's register has no lifecycle type map yet.",
   "title": "Auditor"
  },
  {
   "id": "events",
   "text": "Listing, delisting, name change, domicile change and segment move are not on the record, as this market's register has no lifecycle type map yet. The halt flag is listed, not halted.",
   "title": "Events and halts"
  },
  {
   "id": "orderability",
   "text": "The orderability outcome is not determinable. The chapter's orderability section carries no client categories, so the outcome cannot name its client category. The rule version is acm-68000/se/mifid-ii-product-governance/r1, and the chapter is as of 2026-11-04.",
   "title": "Orderability"
  },
  {
   "id": "coverage",
   "text": "No research houses were found on the investor-relations pages read, so the count is 0.",
   "title": "Coverage"
  },
  {
   "id": "open_research",
   "text": "The record holds 3 openly published research notes, all by Redeye: 2020-12-13, 2022-04-22 and 2022-11-03.",
   "title": "Open research"
  },
  {
   "id": "licensed",
   "text": "Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.",
   "title": "Licensed"
  },
  {
   "id": "depth",
   "text": "The market's vintage is not sealed. No issuer years are sealed, the market's earliest sealed date is not on the record, and the live record start is not on the record.",
   "title": "As-of depth"
  },
  {
   "id": "sources",
   "text": "9 source pages are named on this page; every value above carries its own source page and read date in the numbers.",
   "title": "Sources"
  }
 ],
 "sources": [
  {
   "for": "identity.exchange",
   "source": "https://firds.esma.europa.eu/firds/"
  },
  {
   "for": "identity.lei",
   "source": "https://mapping.gleif.org/api/v2/isin-lei/latest/download"
  },
  {
   "for": "the disclosure lines",
   "source": "https://mcp.se-cm-kg.ai/events/XSTO/SE0029278555"
  },
  {
   "for": "the halt flag",
   "source": "https://api.news.eu.nasdaq.com/news/query.action?globalGroup=exchangeNotice&globalName=ExchangenewsFilter|FirstNorthInformation"
  },
  {
   "for": "the orderability chapter",
   "source": "https://se.eu-cm-kg.ai/book/aio.json"
  },
  {
   "for": "open research",
   "source": "https://www.activebiotech.com/wp-content/uploads/Redeye-active-biotech-q3-2022-approaching-important-milestones-2_ob2rcp.pdf"
  },
  {
   "for": "open research",
   "source": "https://www.activebiotech.com/wp-content/uploads/Redeye_Active_Biotech_Note_Q1_2022.pdf"
  },
  {
   "for": "open research",
   "source": "https://www.activebiotech.com/wp-content/uploads/active-biotech-initation-201214.pdf"
  },
  {
   "for": "the record",
   "source": "https://mcp.se-cm-kg.ai/record/XSTO/SE0029278555"
  }
 ],
 "title": "Active Biotech AB (SE0029278555) — research page",
 "writer": {
  "by": "Claude through the platform account, Haiku class; one pass; checked against the numbers",
  "engine": "claude-haiku-5-5"
 }
}